Good. But AMGN still doesn't have the topline synergy unless FDA drops statin in the label or AMGN acquires a statin maker. IMO, as long as Vascepa is only approved as an adjunct therapy to statin, the potential acquirers will be limited to the usual suspects, i.e., BPs who sell statin.
Wise ...correct I'm on both Repatha and Vascepa . Cardiologists contact their high risk patients . " This is what I want you on... to say out of our ER " Kiwi
Market Data 
Markets 
AI
